Oncolytic vaccinia virus therapy of salivary gland carcinoma.

N. Chernichenko,Gary Linkov,Pingdong Li,R. Bakst,Chun-Hao Chen,Shuangba He,Yong A. Yu,N. Chen,A. Szalay,Y. Fong,R. Wong
DOI: https://doi.org/10.1001/jamaoto.2013.1360
2013-02-01
JAMA Otolaryngology - Head and Neck Surgery
Abstract:OBJECTIVE To examine the therapeutic effects of an attenuated, replication-competent vaccinia virus (GLV-1h68) against a panel of 5 human salivary gland carcinoma cell lines. DESIGN The susceptibility of 5 salivary gland carcinoma cell lines to infection and oncolysis by GLV-1h68 was assessed in vitro and in vivo. RESULTS All 5 cell lines were susceptible to viral infection, transgene expression, and cytotoxic reactions. Three cell lines were exquisitely sensitive to infection by very low doses of GLV-1h68. Orthotopic parotid tumors exhibited more aggressive behavior compared with flank tumors. A single intratumoral injection of GLV-1h68 induced significant tumor regression without observed toxic effects in flank and parotid tumor models; controls demonstrated rapid tumor progression. CONCLUSION These promising results demonstrate significant oncolytic activity by an attenuated vaccinia virus for infecting and lysing salivary gland carcinomas, supporting future clinical trials.
What problem does this paper attempt to address?